Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 689-693

  Chang, Sui Yuan ^a,b   Chen, Mao Yuan ^b   Lee, Chun Nan ^a,b   Sun, Hsin Yun ^b   Ko, Wilson ^a   Chang, Shu Fang ^a   Chang, Kei Lung ^a   Hsieh, Szu Min ^b   Sheng, Wang Huei ^b   Liu, Wen Chun ^b   Wu, Cheng Hsin ^b   Kao, Chuan Liang ^a,b   Hung, Chien Ching ^b   Chang, Shan Chwen ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antiretroviral therapy; Highly active antiretroviral therapy; HIV 1; Non nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Protease inhibitors

Indexed keywords

ATAZANAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; MALE HOMOSEXUAL; MEDICAL SOCIETY; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; NONHUMAN; PREVALENCE; SUPERINFECTION; TAIWAN; TREND STUDY; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; TAIWAN;

EID: 40049092925     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn002     Document Type: Article

References (10)

1. Weinstock HS, Zaidi I, Heneine W et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189: 2174-80.
2. Jayaraman GC, Archibald CP, Kim J et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: Results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 2006; 42: 86-90.
3. Shet A, Berry L, Mohri H et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience. J Acquir Immune Defic Syndr 2006; 41: 439-46.
4. Wensing AM, van de Vijver DA, Angarano G et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192 958.-66.
5. Guidelines for Surveillance of HIV Drug Resistance. World Health Organization, 2003. www.cdc.gov/dls/ila/cd/who-afro/resis-guide12_12.pdf (21 December 2007 date last accessed).
6. Grant RM, Hecht FM, Warmerdam M et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288: 181-8.
7. Oette M, Kaiser R, Daumer M et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006; 41: 573-81.
8. Chang SY, Sheng WH, Lee CN et al. Molecular epidemiology of HIV type 1 subtypes in Taiwan: Outbreak of HIV type 1 CRF07_BC infection in intravenous drug users. AIDS Res Hum Retroviruses 2006; 22: 1055-66.
9. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15: 119-25.
10. Verhofstede C, Wanzeele FV, Van Der Gucht B et al. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999; 13: 2541-6.